<DOC>
	<DOCNO>NCT02862106</DOCNO>
	<brief_summary>The purpose evaluate efficacy safety therapeutic HBV vaccine ( mimogen-based ) treatment chronic hepatitis B patient explore effective dosage provide rational optimal dosing schedule .</brief_summary>
	<brief_title>Second Stage : Open-label Study Therapeutic Hepatitis B Vaccine ( Mimogen-based ) Chronic Hepatitis B</brief_title>
	<detailed_description>Second stage ( 76-144 week ) : In follow-up stage trial open design , subject complete first stage study ( 0-76 week ) 1 . Subjects virological response serological response/with serological response virological response/neither virological serological response first stage , willing continue follow-up study , treat εPA-44 900 μg week 80,83,86,89,92,95,98,101,104,108,112,116,120,124,128 . 2 . Subjects virological serological response , followed-up 144 week Adefovir Dipivoxil εPA-44 900 μg treatment . The definition response : 1 . Virological response : HBV DNA＜2.93×10∧3IU/ml 76 week ; 2 . Serological response : serological conversion HBeAg 76 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . The subject complete first stage study ( 076 week ) willing willing participate trial 2 . Uses effective contraception subject childbearing potential ( include female female partner male ) 3 . Understands sign ICF approve EC 4 . Willing comply study procedure complete study 1.Any factor inappropriate enrollment study study completion view investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>HBeAg positive</keyword>
	<keyword>Therapeutic HBV Vaccine</keyword>
	<keyword>HBV-specific Cytotoxic T Lymphocyte</keyword>
</DOC>